9 Aug 2016 16:04
9 August 2016
Notice of Results
Mereo BioPharma Group plc ("Mereo" or the "Company") (AIM:MPH), a UK-based specialty biopharmaceutical company, will announce its interim results for the six months ended 30 June 2016 on Friday, 16 September 2016.
Enquiries:
Mereo BioPharma Group plc |
+44 (0)333 023 7319 |
Denise Scots-Knight, Chief Executive Officer |
|
Richard Bungay, Chief Financial Officer & COO |
|
|
|
Cantor Fitzgerald Europe (Nominated Adviser and Broker) |
+44 (0)20 7894 7000 |
Phil Davies |
|
Will Goode |
|
Rick Thompson |
|
Callum Butterfield |
|
|
|
RBC Capital Markets (Joint Broker) |
+44 (0)20 7653 4000 |
Paul Tomasic |
|
Rupert Walford |
|
Thomas Stockman |
|
Laura White |
|
|
|
FTI Consulting (Public Relations Adviser) |
+44 (0)20 3727 1000 |
Ben Atwell |
|
Simon Conway |
|
Brett Pollard |
About Mereo
Mereo is a UK-based biopharmaceutical company focused on the development of innovative medicines that aim to address unmet medical needs in rare and specialty disease areas and improve patient quality of life. The Company seeks to selectively acquire development-stage product candidates with demonstrated clinically meaningful data from large pharmaceutical companies and to rapidly progress these product candidates to subsequent value inflection points.
Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. The Company has the option to directly commercialise products, for example in orphan diseases, in addition to partnering or divesting its products.
Mereo's initial portfolio consists of three mid-late stage clinical assets that were acquired from Novartis in July 2015. BPS-804 is being developed for the prevention of fractures resulting from osteogenesis imperfecta (brittle bone disease); BCT-197, is being developed to treat inflammation in patients with an acute exacerbation of chronic obstructive pulmonary disease; and BGS-649 is a once-weekly pill to restore normal testosterone levels in men with hypogonadal hypogonadism.
In H1 2016 the Company initiated a Phase 2 study with BCT-197 and a Phase 2b study with BGS-649. Mereo intends to commence a Phase 2b/3 study during H2 2016 for BPS-804. Additional product opportunities (from a range of large pharmaceutical companies) are under active evaluation.